Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
The core 1β3GalT-specific molecular chaperone (COSMC) is located in X24 encoded by a single gene and acts as a specific molecular chaperone for T-synthase. The Tn antigen caused by mutations in the COSMC gene is one of the most common tumor-associated carbohydrate antigens. COSMC mutations have been observed in the autoimmune disease Tn syndrome and in some tumor cell lines. These findings demonstrate that Tn antigen (GalNAc-Ser/Thr) expression can be controlled by COSMC.
COSMC and PDAC
Human pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and fatal malignancies in the world and despite the tremendous efforts in research types of treatment remain limited. Often detected PDAC changes are truncated O-linked N-acetylgalactosamine (GalNAc) glycosylation with expression of the Tn antigen. Alterations in O-glycosylation affect the post-translationally modified O-GalNAc protein, leading to profound cellular changes. The Tn antigen is a tumor-associated glycan detected in 75-90% of PDAC and is detected up to 67% in its precursor lesions. Studies have found that Tn antigen expression was induced on various O-GalNAc glycoproteins in COSMC-deficient cell lines. Proliferation was reduced in COSMC knockdown cells, and migration was increased and apoptosis was reduced, highlighting the importance of Tn antigen expression for the transfer and anti-apoptotic behavior of PDAC-derived cells. Nucleolins were identified as O-GalNAc modified proteins in COSMC-deficient PDAC cell lines. Interestingly, immunohistochemical staining and co-localization studies of patient-derived PDAC showed that patients with strong co-localization of Tn antigen and nucleolin had lower survival rates. These findings confirmed the effect of altered O-glycan (Tn/STn) expression on the carcinogenic properties of pancreatic cancer and identify O-GalNAc-modified nucleolin as a new prognostic marker.
COSMC and IgAN
IgA nephropathy (IgAN) is one of the most common glomerular diseases leading to end-stage renal failure. The elevation of abnormal glycosylation of IgA1 is a key feature. Expression of a specific chaperone of COSMC is known to be reduced in IgAN. Recent studies have shown that hypermethylation of the COSMC promoter region may be a key mechanism for reducing the expression of COSMC mRNA in IgAN lymphocytes with associated increase in aberrantly glycosylated IgA1.
COSMC and IBD
Inflammatory bowel disease (IBD) is caused by abnormal immune stimulation against the genital mucosa, but relatively retained by the luminal microbiota and preferentially affects males in early onset disease. However, factors that lead to sex-specific risk and the pattern of dysbiosis are largely unexplored. COSMC encodes an important X-linked partner for glycocalyx formation and was recently identified as an IBD risk factor by genome-wide association studies. Matthew R et al. deleted COSMC in mouse intestinal epithelial cells (IECs) and found a significant reduction in microbial diversity in the progression from proximal to distal intestinal mucosa, but not in the overlying lumen, as seen in IBD. This loss of diversity was consistent with locally occurring pro-inflammatory lesions and distal intestinal limited pathology. In mechanism, COSMC regulates host genes, bacterial ligands, and nutrient availability to control microbial biogeography. Deletion of a COSMC allele (IEC- COSMC-/y) in males resulted in impaired mucus layer, spontaneous microbial-dependent inflammation and experimental colitis enhancement; however, females with loss of one allele and mosaic deletion of COSMC in 50% of crypts (IEC- COSMC+/−) were protected from spontaneous inflammation and partially protected from experimental colitis, probably due to the normal migration of normal mucinglycocalyx from the wild-type (WT) cells to the knock-out (KO) crypt. These studies functionally validated COSMC as a risk factor for IBD and linked it to spatial patterns that regulate dysbiosis and gender bias in IBD.
COSMC and colon cancer
The expression of T antigen (Galbeta1) is associated with increased metastatic potential and poor prognosis in colorectal cancer. COSMC is a molecular chaperone required for the formation of active T-synthase, which catalyzes the synthesis of T antigens. However, the expression and role of COSMC in colorectal cancer remains unclear. Real-time PCR showed that overexpression of COSMC mRNA in colorectal tumors was associated with an increase in the tumor stage of the American Joint Committee on Cancer (AJCC) compared to paired non-tumor tissues. Forced expression of COSMC in HCT116 cells significantly increased T antigen expression and enhanced cell growth, migration and invasion, which was associated with increased phosphorylation of focal adhesion kinase (FAK), extracellular regulated protein kinases (ERK) and Protein Kinase B (Akt). These COSMC enhanced malignant phenotypes were significantly inhibited by specific inhibitors of MEK or PI3K. In addition, COSMC overexpression increased tumor growth and reduced survival of SCID mice bearing tumors. In contrast, knockdown of COSMC with Small interfering RNA (siRNA) in SW480 cells reduced malignant behavior and signaling pathways, which were essentially reversed by constitutively active Akt or MEK. In conclusion, these results suggest that COSMC promotes the malignant phenotype of colon cancer cells primarily by activating MEK/ERK and PI3K/Akt signaling pathways, and that COSMC may serve as a potential target for colorectal cancer therapy.
In conclusion, COSMC is critical for the formation of active core 1 synthetase, and mice lacking core 1 synthase or COSMC are embryonic lethal. COSMC is able to convert wild-type proteins into tumor-specific antigens by altering the glycosylation of proteins, which means that COSMC may be an important factor in regulating glycosylation and function of tumor cells.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.